Dominari Holdings Provides Update on Share Repurchase Program
Dominari Holdings Inc. (Nasdaq: DOMH) has initiated a $2 million share repurchase program, authorized on December 5, 2022. As of December 29, 2022, the company has repurchased 5,000 shares at a price of $3.2139 per share. The program allows for additional repurchases depending on market conditions. Dominari is transitioning its business focus to fintech and financial services, following its acquisition of a registered broker-dealer, while continuing its therapeutics development through AIkido Labs, LLC.
- Share repurchase program of $2 million enhances shareholder value.
- Initial repurchase of 5,000 shares indicates confidence in the company's stock.
- None.
NEW YORK, Dec. 30, 2022 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) ("Dominari" or the "Company") today provided an update on the
The Company reported that on December 29, 2022, the Company purchased 5,000 shares of common stock at
Additional shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b -18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, including blackout period restrictions.
About Dominari Holdings Inc.
Dominari Holdings Inc. (f/k/a AIkido Pharma Inc.) until recently was focused primarily on the development of a diverse portfolio of small-molecule anticancer and antiviral therapeutics and related patent technology. In September 2022, the Company agreed to acquire a registered broker-dealer and transition its primary business operations to fintech and financial services. Upon the final closing of this acquisition, the Company's fintech and financial services business will be operated through its subsidiary, Dominari Financial Inc. The Company continues to develop its therapeutics and related patent technology, as well as other ventures, through its subsidiary, AIkido Labs, LLC.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
Dominari Holdings Inc. (f/k/a AIkido Pharma Inc):
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/dominari-holdings-provides-update-on-share-repurchase-program-301711247.html
SOURCE Dominari Holdings Inc.
FAQ
What is the purpose of Dominari Holdings' share repurchase program?
How many shares has Dominari Holdings repurchased under the program?
When was the share repurchase program authorized?
What is the stock symbol for Dominari Holdings?
When was the latest share repurchase completed?
